delandistrogene moxeparvovec sold brand name elevidys recombinant gene therapy used treatment duchenne muscular designed deliver body gene leads production elevidys microdystrophin contains selected domains dystrophin protein present normal muscle adenoassociated virus vectorbased gene therapy given injection commonly reported side effects include vomiting nausea acute liver injury pyrexia fever thrombocytopenia abnormally low platelet count delandistrogene moxeparvovec approved medical use united states june developed sarepta therapeutics manufactured delandistrogene moxeparvovec indicated treatment ambulatory children aged four five years age duchenne muscular dystrophy confirmed mutation dmd delandistrogene moxeparvovec designed deliver body gene leads production elevidys microdystrophin shortened protein kda compared kda dystrophin protein normal muscle cells contains selected domains dystrophin protein present normal muscle cells fda states conditional approval based detection successful gene expression evidence clinical improvement still accelerated us food drug administration fda approval delandistrogene moxeparvovec based data randomized clinical trial established delandistrogene moxeparvovec increased expression elevidys microdystrophin protein observed delandistrogene moxeparvovectreated individuals aged four five years duchenne muscular initial pricing announced million single treatment expected last pharmacologyrelated article stub help wikipedia expanding httpsenwikipediaorgwikidelandistrogenemoxeparvovec